Subcellular metabolism of [3H]-oestrone sulphate in human gestational myometrium.

Human myometrium obtained at caesarean sections from term pregnancies was homogenized and separated into nuclear, mitochondrial, microsomal and cytosol fractions. Purity of the individual fractions was assessed by microscopy and by determination of marker enzymes. Homogenate and subcellular fractions were incubated with [3H]-oestrone sulphate in a concentration of 5 x 10(-10) M after addition of NADPH2 and a coenzyme regenerating system at 37 degrees C.

[Tocolysis with a beta-receptor stimulating compound in patients with WPW-syndrome. A casuistic report (author's transl)].

During a previous pregnancy supraventricular tachycardia complicated delivery in time in a woman with WPW-syndrome (Typ A) known since seven years. In the 34th week of the second pregnancy onset of preterm labor with a pelvic score of 7 and a tocolysis index of 5 was indication for tocolytic therapy. For protection against paroxysmal supraventricular tachycardia tocolysis with the semiselective beta 2-stimulating compound Fenoterol was started in combination with the beta 1-selective blocking compound Metoprolol.

[Efficency of tocoylsis by fenoterol and fenoterol in combination with a beta-1-blocking compound (author's transl)].

In 35 pregnant women threatening premature labour and cervic dilatation indicated therapy by a beta-mimetic compound (fenoterol) for tocolysis. 17 patients (group I) got fenoterol-monotherapy; in 18 patients (group II) fenoterol was combined with the cardioselective beta-1-blocking agent metoprolol. There were no differences in age, bodyweight and time of gestation in both groups before therapy; also the obstetric states--as compared by pelvic score (Bishop) and tocolysis index (Baumgarten)--were nearly identical.

[Clinical application of combined beta 2-stimulation and beta 1-blockade in tocolysis (author's transl)].

35 pregnant women were treated with the semiselective beta 2-stimulating compound fenoterol because of threatening premature labor. The efficiency of tocolysis and the cardiovascular effects of a mono-therapy with fenoterol were compared with a combined therapy with the beta 1-blocking compound metoprolol by the following parameters: Heart rate, systolic and diastolic blood pressure, left ventricular dimensions and mean Vcf as determined by echocardiography, pelvic score, tocolysis-index and tocolysis-success-score (Weidinger-score). Metoprolol caused a remarkable and highly significant reduction of the fenoterol-induced cardiac effects: increase of heart rate and augmentation of mean Vcf; the blood pressure was significantly lowered by metoprolol.

Primary structure of yeast proteinase B inhibitor 2.

The complete amino acid sequence of yeast proteinase B inhibitor 2 (IB2) was determined to be H3N+-Thr-Lys-Asn-Phe-Ile-Val-Thr-Leu-Lys-Lys-Asn-Thr-Pro-Asp-Val-Glu-Ala-Lys-Lys-Phe-Leu-Asp-Ser-Val-His-His-Ala-Gly-Gly-Ser-Ile-Leu-His-Glu-Phe-Asp-Ile-Ile-Lys-Gly-Tyr-Thr-Ile-Lys-Val-Pro-Asp-Val-Leu-His-Leu-Asn-Lys-Leu-Lys-Glu-Lys-His-Asn-Asp-Val-Ile-Glu-Asn-Val-Glu-Asp-Lys-Glu-Val-His-Thr-Asn-COO-. Elucidation of the primary structure was enabled by automated Edman degradation and COOH-terminal hydrolysis with carboxypeptidases A (bovine pancreas and Y (yeast). IB2 is the first proteinase inhibitor to be sequenced that possesses a structure devoid of disulfide bridges.